Loading...

OCGN OCUGEN INC Product Launches 8-K Filing

CGN

CGN

OCUGEN INC

(OCGN)

2026 8-K

Clinical Trial Results

Funding Announcement

Legal Petition Filed

Financial Results Announced

CFO Appointment

Stock Offering Completed

Stock Offering Announcement

Positive Trial Data

CEO Stock Award

Financial Results Announcement

Merger Termination

Exclusive License Agreement

Ocugen Merger Agreement

Financial Statements

Outlook Changes

Delisting due to Non-Compli...

Merger of Equals

Investor Meetings

Financial Statements

Investor Presentation

Financial Results

Investor Presentation

Investor Presentation

Loan Agreement Update

Investor Presentation

Investor Presentation

Management Change

Investor Presentation

Financial Results

Investor Presentation

FDA Notification for Expand...

Public Offering

Appointment of Pricewaterho...

Accounting Firm Change

Financial Results Announcement

Dividend Declaration

Litigation Dismissal

FDA Clearance for Phase 3 T...

Restatement of Financial St...

Litigation Dismissal

Departure of Directors and ...

Presentation at Clinical Sh...

Other Special Situation

Appointment of Interim Chie...

Clinical Study Update

Management Changes

Annual Meeting Results

Presentation at BIO Interna...

Underwriting Agreement

Results of Operations and F...

Positive Preliminary Data a...

Resignation of Chief Accoun...

Appointment and Lawsuit Dis...

Other Special Situation

External Links:

On January 15, 2026, Ocugen, Inc. announced positive preliminary 12-month data from its Phase 1 and Phase 2 trials for OCU410, a gene therapy for eye disease. This filing is significant for investors as it indicates promising progress in their clinical research.

AI Assistant

OCUGEN INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.